Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg

Xilio Therapeutics, Inc.

2023-Q3 EPS reported -$2.14

Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.
Cash $59.8M (Sep 30) vs $120.4M (Dec 31); runway into Q2 2024.
XTX202 Phase 1/2: 50% disease control rate at ≥2.8 mg/kg; no vascular leak syndrome.
XTX101: >70% tumor activation in biopsies; clinical trial collaboration with Roche to start combo with atezolizumab in Q4 2023.
XTX301 preliminary Phase 1 safety data expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Xilio Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.